TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01875237
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
Study: NCT03782662
Drug: Placebo for RV521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for RV521 capsules
Study: NCT01134991
Drug: Topical Minocycline Foam FXFM244
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Study: NCT00905073
Drug: cyclosporin and methotrexate
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
Study: NCT04150393
Drug: MaaT033 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01436448
Drug: Probiotics Lactobacillus Rhamnosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
Study: NCT04294472
Drug: MAU868
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
Study: NCT01763658
Drug: Antox tablets(Mepaco)
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of antioxidant on disease outcome
Study: NCT01169038
Drug: levaquin; ethambutol; rifampin and azithromycin.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway.
Study: NCT03472092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
Study: NCT01573819
Drug: GSK356278
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
Study: NCT01573819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
Study: NCT03077750
Drug: VBP-245 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application BID
Study: NCT03077750
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Control With No Active Pharmaceutical Ingredients
Study: NCT01705483
Drug: ASP9853
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00446290
Drug: Docetaxel, Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01129648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered daily for 21 days
Study: NCT01251393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
Study: NCT01129648
Drug: BCX4208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered daily for 21 days.
Study: NCT04650750
Drug: Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect.
Study: NCT04650750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar placebo 4g twice a day for two months
Study: NCT01273480
Drug: Sequence 1
Normalized name: Antihemophilic Factor (Recombinant) Porcine Sequence 1 U Intravenous Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
Study: NCT01094262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
Study: NCT02142543
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02710214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of placebo for 8 weeks
Study: NCT03710707
Drug: DNL201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT03710707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT03091868
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules. Oral administration.
Study: NCT02466087
Drug: Mg Cl
Normalized name: Saizen 8.8mg Click.Easy Cartridge Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four supplements a day for 6 weeks.
Study: NCT05475431
Drug: The triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
Study: NCT01129648
Drug: BCX4208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminstered daily for 21 days
Study: NCT00528658
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg tid
Study: NCT03129061
Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose.
Study: NCT03129061
Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection.
Study: NCT00528658
Drug: Paracetamol Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equivalent to 1g qid
Study: NCT00528658
Drug: Ibuprofen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent to 400mg tid
Study: NCT02377349
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study: NCT01516554
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT00429299
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/sqm iv day 1 q21 days for four coursess
Study: NCT00429299
Drug: epidoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/sqm iv day 1 q21 days for four courses
Study: NCT00429299
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/sqm day 1 q21 days for four courses
Study: NCT02643784
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Study: NCT01332968
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study: NCT01332968
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Study: NCT01963260
Drug: MK-8723
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study: NCT01963260
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study: NCT00248989
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 ml of placebo cream applied on the skin twice daily.
Study: NCT00466531
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00372996
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
Study: NCT00000317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00004860
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03618108
Drug: Doxycycline Capsule
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline capsule
Study: NCT03618108
Drug: Azithromycin Capsule
Normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin capsule
Study: NCT03618108
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule identical in size and form to doxycycline
Study: NCT04136067
Drug: NNC0268-0965
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
Study: NCT04166058
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
Study: NCT03618108
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule identical in size and form to azithromcyin
Study: NCT03618108
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule identical in size and form to rifabutin
Study: NCT02670785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Study: NCT02661022
Drug: SL-401 7 µg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL-401 7 µg/kg/day in combination with pom/dex
Study: NCT02661022
Drug: SL-401 9 µg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL-401 9 µg/kg/day in combination with pom/dex
Study: NCT00001239
Drug: FLAC with GM-CSF
Normalized name: Flac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02884986
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
Study: NCT02884986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg of placebo
Study: NCT00830167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Study: NCT01985724
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
Study: NCT01985724
Drug: 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study: NCT00003350
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00860925
Drug: ASA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
Study: NCT01259830
Drug: Arcoxia®120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Study: NCT01259830
Drug: P Tablet White Lichtenstein
Normalized name: phentermine Oral Tablet [Adipex-P]
Approvals — FDA: no, EMA: no, PMDA: no
Description: P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
Study: NCT04510168
Drug: [F-18]MK-6240
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging to measure tau; target imaging dose of 4 to 5 mCi
Study: NCT02101476
Drug: Xartemis
Normalized name: Xartemis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/650mg
Study: NCT02361736
Drug: Lactate Ringers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
Study: NCT02474654
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15mcg
Study: NCT02474654
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml
Study: NCT02474654
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30ml
Study: NCT02474654
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml
Study: NCT02474654
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml
Study: NCT02474654
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mcg
Study: NCT02474654
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg
Study: NCT02474654
Drug: Ropivicaine with Epinephrine
Normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% 1:400,000 30ml
Study: NCT01910831
Drug: DerMend Moisturizing Bruise Formula
Normalized name: DerMend Moisturizing Bruise Formula Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
Study: NCT01910831
Drug: Non-active placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active placebo control
Study: NCT01274962
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days.
Study: NCT01186562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04107727
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Study: NCT01007019
Drug: YH4808 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 30mg (single dose)
Study: NCT01007019
Drug: YH4808 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 50mg (single dose)
Study: NCT01007019
Drug: YH4808 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 100mg (single dose)
Study: NCT01007019
Drug: YH4808 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 200mg (single dose)
Study: NCT01007019
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 400mg (single dose)
Study: NCT01007019
Drug: YH4808 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 600mg
Study: NCT01007019
Drug: YH4808 800mg (single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 800mg (single dose)
Study: NCT01007019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 volunteers will be administered matched placebo.
Study: NCT01160640
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg PO bid x 14 days
Study: NCT01160640
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral capsule PO bid x 14 days
Study: NCT00959621
Drug: Klexane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
Study: NCT00002592
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00536198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
Study: NCT02922582
Drug: DepoTXA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension (equal volume to experimental drug) x 45 days
Study: NCT00200655
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00200655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04315272
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
Study: NCT04315272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02376257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT00374166
Drug: SSR149415
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration (capsules of 50 and 100 mg)
Study: NCT00374166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration (capsules)
Study: NCT02643082
Drug: GFF MDI (PT003) 14.4/9.6μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium and Formoterol Fumarate
Study: NCT02643082
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator: Placebo MDI which contains no active ingredients
Study: NCT01120691
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Study: NCT01120691
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Study: NCT01435928
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily in the evening with a meal or 30 minutes after eating